Lille (France), Cambridge (Mass.), January 7, 2008 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111) the biopharmaceutical company at the forefront of research and development of cardiovascular, inflammatory and metabolic drugs today announced a new phase in the evolution of its research collaboration with the PIERRE FABRE Laboratories.
The PIERRE FABRE group and GENFIT have been collaborating on several programs since 2001, and more specifically since 2005 on two drug discovery programs targeting metabolic disorders. The two companies have recently identified a first-in-class group of molecules corresponding to an innovating therapeutic strategy and aiming at a simultaneous effect on Type II diabetes and dyslipidemia and a potential effect on obesity, specifically through a phenotypic approach...
[PDF] GENFIT's Press Release- PDF du Communiqué de Presse GENFIT-
